Domenico Criscuolo

Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy.